news
JPND launches €23 million call for neurodegenerative disease research
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
List view / Grid view
Alzheimer’s disease
news
Benzodiazepines increase stroke risk in Alzheimer’s patients
The use of benzodiazepines and benzodiazepine-like drugs was associated with a 20% increased risk of stroke among persons with Alzheimer’s disease, shows a recent study from the University of Eastern Finland.
news
Researchers find a potential target for anti-Alzheimer treatments
The USP9 gene has an indirect influence on the so-called tau protein, which is believed to play a significant role in the onset of Alzheimer’s disease.
article
A is for Alzheimer’s disease
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A is for Alzheimer's - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the fight against this deadly disease
news
Tweaking immune response key to combat neurodegeneration
19 October 2016 | By Niamh Louise Marriott, Digital Content Producer
A better understanding of how we could manipulate immune system conditions might aid to develop novel therapies against Alzheimer's, Kizil argues...
news
Brain diseases manifest in the retina of the eye
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Dr Henri Leinonen investigated functional abnormalities of the retina using mouse models of human central nervous system diseases...
news
Targeting nicotine receptors could prevent Alzheimer’s memory loss
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The scientists were able to prove that the β2 subunit of the nicotinic receptor is the direct target of soluble amyloid beta peptide...
news
Elevating brain protein allays Alzheimer’s symptoms and improves memory
25 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The protein, called neuregulin-1, has many forms and functions across the brain and is already a potential target for brain disorders such as Alzheimer's disease, amyotrophic lateral sclerosis and schizophrenia...
news
Alzheimer’s research shows period pain-killer completely reverses memory loss
11 August 2016 | By University of Manchester
Transgenic mice that develop symptoms of Alzheimer's disease were used with one group of 10 treated with mefenamic acid, and 10 with a placebo. The mice were treated at a time when they had developed memory problems. After one month's treatment, memory loss was completely reversed back to the levels…
news
Epidarex Capital launches Nodthera Limited
28 July 2016 | By Epidarex Capital
Epidarex Capital announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome...
news
Antibiotics weaken Alzheimer’s disease progression
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Antibiotic treatment decreases levels of disease-causing plaques, a hallmark of Alzheimer's disease, according to a new study by neuroscientists...
news
Alzheimer’s tau spreads through brain via extracellular space
19 July 2016 | By Victoria White, Digital Content Producer
Karen Duff of Columbia University says that learning how tau spreads may lead to therapies that stop the toxic protein from jumping between neurons...
whitepaper
Whitepaper: Accelerating drug discovery for Alzheimer’s disease: best practices for preclinical animal studies
In this whitepaper, ADDF partner with Charles River and an expert advisory panel of academic, industry and government scientists to make recommendations on best practices for animal studies testing investigational AD therapies...
news
New mouse model suggests how Alzheimer’s causes dementia
4 July 2016 | By Victoria White, Digital Content Producer
Using a mouse model that mimics the development of Alzheimer’s, scientists have determined the biological “insults” that must occur to cause dementia...
news
Probiodrug and Crossbeta team up for Alzheimer’s disease biomarkers
30 June 2016 | By Victoria White, Digital Content Producer
The partnership will allow Probiodrug to utilise Crossbeta’s proprietary technology in support of Probiodrug’s biomarker development activities...
